Servier, a global independent pharmaceutical Group, and Nymirum, a company focused on RNA-targeted small molecules, announced on Monday that they have signed a strategic collaboration to identify and develop RNA-modulatory drugs to treat neurological diseases.
According to the collaboration agreement, Nymirum is to use its proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting Platform) to discover novel small molecule therapeutics for multiple neurological targets. Servier will be responsible for joint preclinical development and has the right to pursue further development on the present targets and expand its scope. The partnership offers Nymirum with an initial payment, followed by future success payments.
Joshua Fairbank, chief executive officer and co-founder of Nymirum, said, 'We are excited to pair Nymirum's expertise in targeting RNA with Servier's experience in CNS (Central Nervous System) to advance transformative therapies. The ability to resolve and leverage RNA's dynamic structure opens a new chapter for drug discovery, enabling novel programs across all therapeutic areas. Thanks to its expertise in CNS and small molecule therapeutics, Servier is a valuable partner in this collaboration, and together we look forward to accelerating the search for treatments for patients with severe neurological disorders.'
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials